UNCY News and Press, Unicycive Therapeutics Inc. From 03/23/22

LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Unicycive team, together with the Company’s Chief Executive O...

Unicycive to Present at Upcoming March Investor Conferences Presentations to highlight Company's novel treatments for kidney diseases PR Newswire LOS ALTOS, Calif. , March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a cli...

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting Data support potential efficacy and safety of Renazorb for the treatment of hyperphosphatemia in chronic kidney disease PR Newswire ...

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire LOS ALTOS, Calif. , Jan. 10, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies f...

Unicycive Therapeutics (NASDAQ:UNCY) perks up 6.2% premarket after providing an update on the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). In a recent Type C in...

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway On-track to submit New Drug Application in Q4 2022 PR Newswire LOS ALTOS, Calif. , Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-...

Unicycive Therapeutics (NASDAQ:UNCY): Q3 GAAP EPS of $0.37. As of September 30, 2021, cash and cash equivalents totaled $18 million. Press Release For further details see: Unicycive Therapeutics reports Q3 results

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results Expect to receive confirmatory guidance on Renazorb regulatory pathway from the U.S. Food and Drug Administration in Q4 2021 PR Newswire LOS ALTOS, Calif. , Nov. 11, 2021 /PRNewswire/ --&#x...

Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy PR Newswire LOS ALTOS, Calif. , Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies...

The following slide deck was published by Unicycive Therapeutics, Inc. in conjunction with this event. For further details see: Unicycive Therapeutics (UNCY) Investor Presentation - Slideshow